ArticleBMC nephrology2020
Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Article in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Perspectives of Indigenous Peoples on Home Dialysis: A Systematic Review and Meta-Synthesis of Qualitative Studies.Clinical journal of the American Society of Nephrology : CJASN · 2026Pooled it
- A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Barriers and Opportunities in Access to Peritoneal Dialysis across Veterans Health Administration.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.Nature reviews. Nephrology · 2025Review
- Home care program with telemonitoring for patients undergoing peritoneal dialysis in South Korea: a cost-utility analysis.Kidney research and clinical practice · 2025Article
- Unveiling Challenges Hindering the Growth of Home Dialysis in Finland: Insights From 40 Years of Experience.Hemodialysis international. International Symposium on Home Hemodialysis · 2025Article
- Navigating the Global Economic Landscape of Dialysis: A Summary of Expert Opinions from The 4th International Congress of Chinese Nephrologists.Kidney diseases (Basel, Switzerland) · 2024Review
- Selection of dialysis methods for end-stage kidney disease patients with diabetes.World journal of diabetes · 2024Review
- Integrated home dialysis model: facilitating home-to-home transition.Clinical kidney journal · 2024Article
- Estimated indirect costs of haemodialysis versus peritoneal dialysis from a patients' perspective at an Academic Hospital in Pretoria, South Africa.BMC health services research · 2023Article
- Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China.Frontiers in pharmacology · 2023Article
- Should More Patients with Kidney Failure Bring Treatment Home? What We Have Learned from COVID-19.Kidney diseases (Basel, Switzerland) · 2022Review
- Cost-effectiveness analysis of hemodialysis plus hemoperfusion versus hemodialysis alone in adult patients with end-stage renal disease in China.Annals of translational medicine · 2021Article
- Tackling Dialysis Burden around the World: A Global Challenge.Kidney diseases (Basel, Switzerland) · 2021Article
- Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China.BMJ open · 2021Article
- Chronic kidney failure following lancehead bite envenoming: a clinical report from the Amazon region.The journal of venomous animals and toxins including tropical diseases · 2020Article
- Article
- Article
- Declaration of Santo Domingo: commitment to improve education, regulations, public policies, and access to peritoneal dialysis in Latin America.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study aimed to determine the lifetime cost-effectiveness of first-line dialysis modalities for end-stage renal disease (ESRD) patients under the "Peritoneal Dialysis First" policy.
methodsLifetime cost-effectiveness analyses from both healthcare provider and societal perspectives were performed using Markov modelling by simulating at age 60. Empirical data on costs and health utility scores collected from our studies were combined with published data on health state transitions and survival data to estimate the lifetime cost, quality-adjusted life-years (QALYs) and cost-effectiveness of three competing dialysis modalities: peritoneal dialysis (PD), hospital-based haemodialysis (HD) and nocturnal home HD.
resultsFor cost-effectiveness analysis over a lifetime horizon from the perspective of healthcare provider, hospital-based HD group (lifetime cost USD$142,389; 6.58 QALYs) was dominated by the PD group (USD$76,915; 7.13 QALYs). Home-based HD had the highest effectiveness (8.37 QALYs) but with higher cost (USD$97,917) than the PD group. The incremental cost-effectiveness ratio (ICER) was USD$16,934 per QALY gained for home-based HD over PD. From the societal perspective, the results were similar and the ICER was USD$1195 per QALY gained for home-based HD over PD. Both ICERs fell within the acceptable thresholds. Changes in model parameters via sensitivity analyses had a minimal impact on ICER values.
conclusionsThis study assessed the cost-effectiveness of dialysis modalities and service delivery models for ESRD patients under "Peritoneal Dialysis First" policy. For both healthcare provider and societal perspectives, PD as first-line dialysis modality was cost-saving relative to hospital-based HD, supporting the existing PD First or favoured policy. When compared with PD, Nocturnal home Home-based HD was considered a cost-effective first-line dialysis modality for ESRD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.